Paclitaxel

製品コードS1150 別名:NSC 125973

Paclitaxel化学構造

分子量(MW):853.91

Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

サイズ 価格(税別)  
In DMSO JPY 17100
JPY 13600
JPY 46800
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(57)

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
ターゲット
Microtubule (human endothelial cells) [1]
0.1 pM
体外試験

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXUTWM2OD1yLkCwNFI5PyEQvF2= NEHuZ3VUSU6JRWK=
LC-2-ad M1LNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMECwN|E4KM7:TR?= MnjTV2FPT0WU
RL95-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLSTWM2OD1yLkCwNFY3QCEQvF2= MnLlV2FPT0WU
MZ1-PC M4qx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwMECwO|I6KM7:TR?= NULiUlVLW0GQR1XS
TE-8 M3y0d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3oTWM2OD1yLkCwNVE4KM7:TR?= NV\NNllpW0GQR1XS
SW954 NWnBUZJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LEUGlEPTB;MD6wNFEyQSEQvF2= NUGwd442W0GQR1XS
TE-11 M1v5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITpVJZKSzVyPUCuNFAyOjNizszN NYH3bHZEW0GQR1XS
PSN1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGiycFRKSzVyPUCuNFAyOyEQvF2= NHf3eJBUSU6JRWK=
MOLT-4 MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwMECxOFkh|ryP NWS4VW1JW0GQR1XS
697 NXfKcVFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXwTWM2OD1yLkCwNVUh|ryP NHTDUodUSU6JRWK=
ETK-1 M4TXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnX2TWM2OD1yLkCwNVUzKM7:TR?= MmfHV2FPT0WU
TE-10 NGjCNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUOwNnBvUUN3ME2wMlAxOTV2IN88US=> MUnTRW5ITVJ?
HUTU-80 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMECxOlgh|ryP NIO1T2lUSU6JRWK=
NTERA-S-cl-D1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTGTWM2OD1yLkCwNlA6KM7:TR?= Mn62V2FPT0WU
MFH-ino M1nMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3QNopKSzVyPUCuNFAzPjhizszN MmXDV2FPT0WU
IA-LM MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Lm[GlEPTB;MD6wNFI5KM7:TR?= M3fhdHNCVkeHUh?=
MC116 NYXTWZlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELs[IFKSzVyPUCuNFAzQDlizszN Ml;GV2FPT0WU
RKO NFLXNllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTubY5nUUN3ME2wMlAxOjl6IN88US=> NXTyfJJDW0GQR1XS
MRK-nu-1 NXP6fmU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HOXmlEPTB;MD6wNFI6QSEQvF2= M{\XVnNCVkeHUh?=
VA-ES-BJ NITrO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYWwTnBzUUN3ME2wMlAxOyEQvF2= NHvVOohUSU6JRWK=
KALS-1 NF7CRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwMECzNFgh|ryP NH7wco5USU6JRWK=
BB30-HNC M3XKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\VTWM2OD1yLkCwN|E1KM7:TR?= MYrTRW5ITVJ?
ACN MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMECzNVYh|ryP MWfTRW5ITVJ?
TE-9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMECzNlYh|ryP MVLTRW5ITVJ?
SIG-M5 NUG1TolsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMECzNlch|ryP MUfTRW5ITVJ?
no-10 NYjLN5ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4O2eGlEPTB;MD6wNFM3OiEQvF2= NGLKUJRUSU6JRWK=
EW-1 MnXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u5[mlEPTB;MD6wNFM4OSEQvF2= MnvKV2FPT0WU
SK-LMS-1 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[wdGpFUUN3ME2wMlAxPDBzIN88US=> NXyyTYVvW0GQR1XS
GT3TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVOwWG1SUUN3ME2wMlAxPDN2IN88US=> NGPyTG9USU6JRWK=
ES4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTMTWM2OD1yLkCwOFQ6KM7:TR?= NG\ZW45USU6JRWK=
IMR-5 M3\EUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwMEC0OUDPxE1? NXPSUHQ6W0GQR1XS
NCI-H1648 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEC0Olkh|ryP MX;TRW5ITVJ?
MV-4-11 NVm4XFljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHO2eHlKSzVyPUCuNFA1PzVizszN MmO3V2FPT0WU
SK-UT-1 M4PVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULPN3E2UUN3ME2wMlAxPDhizszN NFzXcoFUSU6JRWK=
NB13 NHfDd4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7nTWM2OD1yLkCwOFkyKM7:TR?= MVLTRW5ITVJ?
DJM-1 M3P1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7J[WVKSzVyPUCuNFA2OyEQvF2= Mm\vV2FPT0WU
ES8 M2D1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfRTWM2OD1yLkCwOVM5KM7:TR?= NIHMPIRUSU6JRWK=
TE-6 NX\CPIE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\lTWM2OD1yLkCwOVch|ryP NV7L[phlW0GQR1XS
KS-1 NWT2fGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;hXWRTUUN3ME2wMlAxPTh{IN88US=> NXjPe49bW0GQR1XS
TE-1 NXPnPHlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;zc5NKSzVyPUCuNFA3ODZizszN NYHDW45MW0GQR1XS
ATN-1 M3K4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEC2NFkh|ryP NWXOTpJyW0GQR1XS
A4-Fuk M{DhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMEC2NVEh|ryP MVrTRW5ITVJ?
ALL-PO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHT1SnRKSzVyPUCuNFA3OyEQvF2= NWHxS5k3W0GQR1XS
BE-13 NIjDRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\EUWlEPTB;MD6wNFY{PiEQvF2= NXvGW3hMW0GQR1XS
KM12 M13hNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvGTWM2OD1yLkCwOlM4KM7:TR?= NV;DUFJGW0GQR1XS
NOS-1 NWrEdYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7XTWM2OD1yLkCwOlUh|ryP NUnqRVR5W0GQR1XS
SW962 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\YTWM2OD1yLkCwOlYzKM7:TR?= MnzNV2FPT0WU
OCUB-M NX[x[GFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPkeFdKSzVyPUCuNFA3PjJizszN M2jNU3NCVkeHUh?=
NCI-H510A NH7wZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETxepRKSzVyPUCuNFA3PjVizszN NW[4cWNIW0GQR1XS
EW-16 Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEC2PVQh|ryP MnOzV2FPT0WU
KGN MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMEC3NVIh|ryP NYXobI1OW0GQR1XS
LS-411N M{n6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnVTWM2OD1yLkCwO|E4KM7:TR?= M2PhVXNCVkeHUh?=
Becker M4XqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDqTWM2OD1yLkCwO|Ih|ryP MYLTRW5ITVJ?
HC-1 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PaV2lEPTB;MD6wNFczOSEQvF2= NWTsblhtW0GQR1XS
CESS NIrkN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rLemlEPTB;MD6wNFc{PyEQvF2= NFvwV2NUSU6JRWK=
KURAMOCHI NHTTOndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vqc2lEPTB;MD6wNFc1QCEQvF2= M3nzZXNCVkeHUh?=
TGBC24TKB MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEC3OVIh|ryP MoHjV2FPT0WU
SW982 NH3LWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3VTWM2OD1yLkCwO|Y3KM7:TR?= M2i2b3NCVkeHUh?=
HCE-4 NUe4[3hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XpeWlEPTB;MD6wNFc3PyEQvF2= MXjTRW5ITVJ?
LOUCY NG[zbnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\3VWVNUUN3ME2wMlAxPzd3IN88US=> M172SXNCVkeHUh?=
8-MG-BA NWrSUI9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfPfY1KSzVyPUCuNFA4QTZizszN NEXRNndUSU6JRWK=
HT-144 M2\BTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPqXZRCUUN3ME2wMlAxQCEQvF2= NWr5VpFQW0GQR1XS
LXF-289 NVXGdWQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PpO2lEPTB;MD6wNFgyQCEQvF2= NID4U4FUSU6JRWK=
RS4-11 M3j4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS1UotKSzVyPUCuNFA5OzZizszN MV;TRW5ITVJ?
DEL M{DsN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLhTWM2OD1yLkCwPFQ2KM7:TR?= M363dHNCVkeHUh?=
OCI-AML2 NGLhW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XyNGlEPTB;MD6wNFg2OiEQvF2= NFy0VoZUSU6JRWK=
CCRF-CEM NYfmcXFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnB[ZFVUUN3ME2wMlAxQDdzIN88US=> M4jTfXNCVkeHUh?=
A388 M4j2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\6XWtWUUN3ME2wMlAxQDd2IN88US=> NUjaOZVWW0GQR1XS
KNS-42 NHLGZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHv0Z3JKSzVyPUCuNFA5QTFizszN M13Dd3NCVkeHUh?=
OVCAR-4 M2XqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17xbmlEPTB;MD6wNFkxPCEQvF2= MWfTRW5ITVJ?
NCI-H1355 NHvDO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\6WXc{UUN3ME2wMlAxQTF2IN88US=> NH;TXlRUSU6JRWK=
BL-70 NEfYdIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:5UXZ[UUN3ME2wMlAxQTNizszN NH7wTo5USU6JRWK=
BL-41 NUnINWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ywZWlEPTB;MD6wNFk{PCEQvF2= M3HuXnNCVkeHUh?=
A101D NXO0N|JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEC5OkDPxE1? NIDF[FhUSU6JRWK=
HL-60 NInCfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTyUJpPUUN3ME2wMlAxQTZ4IN88US=> MojHV2FPT0WU
COR-L279 NWfadI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHS4ZWxKSzVyPUCuNFA6QTlizszN NUfXcYFvW0GQR1XS
NCI-SNU-16 NXe5fnF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi1b49KSzVyPUCuNFExODhizszN M4fObXNCVkeHUh?=
Calu-6 NIXtfFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy4bHpKSzVyPUCuNFExOTJizszN M2PUSnNCVkeHUh?=
SR NXnrcGh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\TS|ZGUUN3ME2wMlAyODJ4IN88US=> MV3TRW5ITVJ?
QIMR-WIL MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEGwN|Mh|ryP M{f0eXNCVkeHUh?=
LB647-SCLC M1\Ifmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWf2bVZkUUN3ME2wMlAyODVzIN88US=> NUTqRlZyW0GQR1XS
RPMI-8226 M4LMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\aNnhKSzVyPUCuNFEyODJizszN M3;KVHNCVkeHUh?=
SK-PN-DW NF7VZXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGyTWM2OD1yLkCxNVEzKM7:TR?= NG\TZ5pUSU6JRWK=
SF268 M3j5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPFcmJMUUN3ME2wMlAyOTVzIN88US=> NFu5TIVUSU6JRWK=
HD-MY-Z NEf2VZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEGxOlMh|ryP MVrTRW5ITVJ?
DOHH-2 NInkWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMEGyNFMh|ryP MlvwV2FPT0WU
SCC-3 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXMTWM2OD1yLkCxNlA1KM7:TR?= NHWyXohUSU6JRWK=
ST486 NFK2U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH1UZJjUUN3ME2wMlAyOjB2IN88US=> NVTHZXhPW0GQR1XS
NALM-6 NXTNdFEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLpb41KSzVyPUCuNFEzOTRizszN NWPsdWk3W0GQR1XS
NCI-H1436 NXnMNZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMEGyN|Eh|ryP MUTTRW5ITVJ?
KE-37 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwMEGyN|Qh|ryP Mnz1V2FPT0WU
RPMI-8402 NGfBRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rKWWlEPTB;MD6wNVI2PiEQvF2= M{jrUnNCVkeHUh?=
RXF393 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLXOWNnUUN3ME2wMlAyOjV5IN88US=> NUjoTYNOW0GQR1XS
KARPAS-45 NFewc|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEGyO{DPxE1? NI\uW4JUSU6JRWK=
HOP-62 NVS5UWZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\IdlV5UUN3ME2wMlAyOjd4IN88US=> MUfTRW5ITVJ?
ES1 M2rOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHFbmJKSzVyPUCuNFEzQDhizszN MlvxV2FPT0WU
L-363 M2n5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL6WpdKSzVyPUCuNFE{PTFizszN NWL6d5ZoW0GQR1XS
GI-1 NYDSW|ZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HhVWlEPTB;MD6wNVM4OyEQvF2= NUDUd3lqW0GQR1XS
CTV-1 Mm\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[1ZndKSzVyPUCuNFE1PzhizszN NFH6UJNUSU6JRWK=
TE-5 M1\BcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXMS3VoUUN3ME2wMlAyPDl4IN88US=> NIXi[IVUSU6JRWK=
SNU-C2B NUHpOmkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vBPWlEPTB;MD6wNVQ6PiEQvF2= MYDTRW5ITVJ?
K-562 NH3ROoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjlTWM2OD1yLkCxOVE3KM7:TR?= M4nFXnNCVkeHUh?=
SNB75 M1rQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jrV2lEPTB;MD6wNVU1KM7:TR?= MUXTRW5ITVJ?
MOLT-13 MlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH2TWM2OD1yLkCxOlM4KM7:TR?= M2nGW3NCVkeHUh?=
LS-123 M3jkUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEG2OlQh|ryP NXf3bXY2W0GQR1XS
NCI-SNU-5 NGfLRpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEG3NFEh|ryP NHPHXldUSU6JRWK=
Daudi MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEG3NFgh|ryP NGW2ephUSU6JRWK=
A253 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEG3N|gh|ryP NIDDOHBUSU6JRWK=
TGBC1TKB MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f3XWlEPTB;MD6wNVc2OiEQvF2= NFvteHhUSU6JRWK=
SJSA-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEG3Olch|ryP NFP0[o5USU6JRWK=
NCCIT MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\z[lJKSzVyPUCuNFE4PjlizszN MUDTRW5ITVJ?
NCI-H69 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGWyOFBKSzVyPUCuNFE4PzhizszN MXnTRW5ITVJ?
SH-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfCOZhKSzVyPUCuNFE5QTVizszN MoW2V2FPT0WU
HCC1187 M{DBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEG5NlQh|ryP M1\PZnNCVkeHUh?=
HCC1599 NXnjXZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml73TWM2OD1yLkCyNFIh|ryP MUHTRW5ITVJ?
ONS-76 NFzhRZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL1Z4NTUUN3ME2wMlAzODN4IN88US=> M3T1cXNCVkeHUh?=
KU812 NX\KVnVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLqR5VKSzVyPUCuNFIxOzlizszN NYfsenNPW0GQR1XS
ML-2 M4OyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqwTWM2OD1yLkCyNFQ4KM7:TR?= MXvTRW5ITVJ?
HCE-T MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH4fFZKSzVyPUCuNFIxQTJizszN MlHCV2FPT0WU
NCI-H446 NFfHT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEKxNVIh|ryP NXTPXXF[W0GQR1XS
RPMI-6666 NHHucYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LkXmlEPTB;MD6wNlE1QSEQvF2= M37yWXNCVkeHUh?=
MOLT-16 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjDZYkxUUN3ME2wMlAzOTV|IN88US=> MXfTRW5ITVJ?
JiyoyeP-2003 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\K[2tOUUN3ME2wMlAzOTd4IN88US=> MXfTRW5ITVJ?
MHH-PREB-1 NELURohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTBwMEKxPVEh|ryP M3nEV3NCVkeHUh?=
MC-CAR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPEWY06UUN3ME2wMlAzOzJ4IN88US=> NX35eppLW0GQR1XS
BC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HOSmlEPTB;MD6wNlM1PCEQvF2= MoXKV2FPT0WU
KINGS-1 NGT2T4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\2WXk5UUN3ME2wMlAzOzV3IN88US=> NIPiTnVUSU6JRWK=
PF-382 NVT2O3gyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfHeWZKSzVyPUCuNFI{PzhizszN NVnXUVBjW0GQR1XS
J-RT3-T3-5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorJTWM2OD1yLkCyN|g{KM7:TR?= MmPGV2FPT0WU
SF539 M2rBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMEK0NFEh|ryP MoPYV2FPT0WU
LB831-BLC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj5doVrUUN3ME2wMlAzPDh3IN88US=> NWj6dIppW0GQR1XS
DMS-114 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj3W|RKSzVyPUCuNFI2ODJizszN Mki1V2FPT0WU
LB1047-RCC M{\iRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XLUWlEPTB;MD6wNlUyKM7:TR?= M33qXnNCVkeHUh?=
LB771-HNC Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDUN5JuUUN3ME2wMlAzPTN2IN88US=> NWGyOGdkW0GQR1XS
BB65-RCC MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zsUmlEPTB;MD6wNlU{PCEQvF2= NFGzSoNUSU6JRWK=
BV-173 NGnHT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknYTWM2OD1yLkCyOVU1KM7:TR?= MVfTRW5ITVJ?
ARH-77 M2PSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzuTWM2OD1yLkCyOlAyKM7:TR?= MWfTRW5ITVJ?
IST-MEL1 MmXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTHTWM2OD1yLkCyOlI{KM7:TR?= M17HXnNCVkeHUh?=
NB1 M1zacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwMEK2PFch|ryP MljOV2FPT0WU
EoL-1-cell Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4K3Z2lEPTB;MD6wNlY5QCEQvF2= NX;UdJp6W0GQR1XS
KY821 NILqOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\Xc4ZKSzVyPUCuNFI3QTdizszN NX\LeolkW0GQR1XS
CMK Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIeyNoxKSzVyPUCuNFI4OzRizszN M3P2XnNCVkeHUh?=
NCI-H2126 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonkTWM2OD1yLkCyO|Y5KM7:TR?= MnXsV2FPT0WU
NCI-H526 NWO2dVJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGftW49KSzVyPUCuNFI5QTFizszN NXrBbWd[W0GQR1XS
COLO-684 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPYTWM2OD1yLkCyPVA5KM7:TR?= MXfTRW5ITVJ?
NCI-H747 M3r5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEK5N|Mh|ryP M2DIVHNCVkeHUh?=
JAR Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLjTWM2OD1yLkCyPVQ3KM7:TR?= MoTSV2FPT0WU
MEG-01 NV20OmR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEK5O|gh|ryP MWLTRW5ITVJ?
MONO-MAC-6 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PtPGlEPTB;MD6wN|AzOyEQvF2= NUTJdmxmW0GQR1XS
IST-SL1 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3MbIxIUUN3ME2wMlA{ODR{IN88US=> M3LPR3NCVkeHUh?=
CPC-N MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMEOwO|kh|ryP MnKxV2FPT0WU
NCI-H1963 NGDGdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPs[WtKSzVyPUCuNFMyOzFizszN NVH3W3lnW0GQR1XS
K052 MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF65UolKSzVyPUCuNFMzPDdizszN M4PwVXNCVkeHUh?=
KM-H2 NEXORm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\NTWM2OD1yLkCzN|A4KM7:TR?= NVHRPVJsW0GQR1XS
TE-12 M3zBcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH3TWM2OD1yLkCzN|A6KM7:TR?= MUjTRW5ITVJ?
TK10 M4\sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTyOpJKSzVyPUCuNFM{PTZizszN NIPjWpdUSU6JRWK=
NMC-G1 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEO0OVIh|ryP MmXCV2FPT0WU
no-11 NHjEd2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMEO0O|gh|ryP NEDDcXJUSU6JRWK=
NCI-H524 NFW3T|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XS[GlEPTB;MD6wN|UzQSEQvF2= NF;PNYVUSU6JRWK=
MHH-CALL-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HwUGlEPTB;MD6wN|U3OiEQvF2= NU\oVIFSW0GQR1XS
GB-1 MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkW4TWM2OD1yLkCzOkDPxE1? Ml\EV2FPT0WU
OPM-2 NI\STFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMWotKSzVyPUCuNFM3PzNizszN MWLTRW5ITVJ?
RH-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPRXlIyUUN3ME2wMlA{QDF7IN88US=> NGCzNVBUSU6JRWK=
NCI-H64 NFK2b2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPoTWM2OD1yLkCzPFU4KM7:TR?= MoHjV2FPT0WU
EVSA-T NWDPRXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnnfoNKSzVyPUCuNFM6OjNizszN MkPiV2FPT0WU
KARPAS-299 NGXkcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom1TWM2OD1yLkCzPVgh|ryP Mo[0V2FPT0WU
MZ7-mel MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMESwOEDPxE1? M3nOeXNCVkeHUh?=
LB373-MEL-D MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnGRXJ2UUN3ME2wMlA1OTB3IN88US=> MmOwV2FPT0WU
HEL NV7TSlhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rObmlEPTB;MD6wOFE1KM7:TR?= MmD2V2FPT0WU
SW872 NWnoTXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PYdWlEPTB;MD6wOFIyKM7:TR?= NH;MVmFUSU6JRWK=
DU-4475 NYjCZY12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LBXGlEPTB;MD6wOFI1PCEQvF2= NWXhfmpjW0GQR1XS
IST-SL2 MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\mTWM2OD1yLkC0Nlc2KM7:TR?= M3LTdHNCVkeHUh?=
NCI-H82 NGLneFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OwVGlEPTB;MD6wOFMxPyEQvF2= NUK1R2JlW0GQR1XS
LC4-1 M1fkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjHb3JtUUN3ME2wMlA1OzVzIN88US=> M1\sTXNCVkeHUh?=
HDLM-2 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fQ[GlEPTB;MD6wOFM6OiEQvF2= MlqzV2FPT0WU
MMAC-SF NY\IVYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jSe2lEPTB;MD6wOFU{PCEQvF2= M1TxNnNCVkeHUh?=
L-540 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMES2N|kh|ryP NFLYUlVUSU6JRWK=
MZ2-MEL NV24ZlZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HHdWlEPTB;MD6wOFc1OiEQvF2= MVLTRW5ITVJ?
LU-134-A NG\qdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7XTWM2OD1yLkC0O|c{KM7:TR?= M1PFeXNCVkeHUh?=
UACC-257 Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjO[YtiUUN3ME2wMlA1QDR7IN88US=> NGTKdWFUSU6JRWK=
NCI-H1581 M4fEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\BSGlEPTB;MD6wOFk2OyEQvF2= MmfaV2FPT0WU
NB17 M1v5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nNSGlEPTB;MD6wOFk4QSEQvF2= NF33SnhUSU6JRWK=
SBC-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDDPXVKSzVyPUCuNFUxPDJizszN NEXHUFBUSU6JRWK=
TALL-1 NGPWclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjHNFhKSzVyPUCuNFUxPDVizszN NH;VXGhUSU6JRWK=
NCI-H1304 M1LUXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEWyNFgh|ryP Ml;XV2FPT0WU
NEC8 NHXpWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTBwMEWyPFYh|ryP Mm\wV2FPT0WU
CAL-148 MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\vcYxDUUN3ME2wMlA2PDN7IN88US=> NYTEZZdtW0GQR1XS
CGTH-W-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfsTWM2OD1yLkC1OFQ6KM7:TR?= MnXaV2FPT0WU
NCI-H889 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T1dmlEPTB;MD6wOVU6OiEQvF2= NG\JTHlUSU6JRWK=
GR-ST MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzOTWM2OD1yLkC1OlIyKM7:TR?= MYPTRW5ITVJ?
KARPAS-422 NXnheGo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrvTWM2OD1yLkC1OlUh|ryP NVTBVo1yW0GQR1XS
RPMI-8866 M1fqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkixTWM2OD1yLkC1O|EzKM7:TR?= NV65SlZJW0GQR1XS
SCLC-21H NFz4coFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEW4PFQh|ryP MoD0V2FPT0WU
COR-L88 NWPSc4t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT1SXpKSzVyPUCuNFU6OjdizszN NYHxfmxIW0GQR1XS
LU-139 NEP3fGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LPNmlEPTB;MD6wOVk5PiEQvF2= NHm1UVFUSU6JRWK=
SF126 M4XwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwME[xN|Mh|ryP MmHaV2FPT0WU
NCI-H1882 NY[0Zm5nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwME[0NlQh|ryP MnK2V2FPT0WU
EW-24 NF\PXmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HlemlEPTB;MD6wOlQ5OyEQvF2= NXnHR45{W0GQR1XS
CP67-MEL MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1yLkC2PFEh|ryP M2myVXNCVkeHUh?=
DG-75 Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG5TWM2OD1yLkC2PFk6KM7:TR?= MWHTRW5ITVJ?
LOXIMVI NULZ[Io3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjhbGxKSzVyPUCuNFcxOjhizszN Mm\ZV2FPT0WU
HH M{fqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzyN|VKSzVyPUCuNFcyPTdizszN M1\BUXNCVkeHUh?=
K5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\Zem5CUUN3ME2wMlA4OjJ4IN88US=> NGLlRZlUSU6JRWK=
EC-GI-10 NX3veYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX64XGd6UUN3ME2wMlA4OjV5IN88US=> MnLkV2FPT0WU
SK-N-DZ NEHnb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLlRlF6UUN3ME2wMlA4OzB5IN88US=> MnHsV2FPT0WU
A3-KAW NY\JXo9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WzcGlEPTB;MD6wO|M2OSEQvF2= M2Hqb3NCVkeHUh?=
MLMA NWKxeZZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfQe2ZjUUN3ME2wMlA4PDZ3IN88US=> MWPTRW5ITVJ?
LB996-RCC NIT0T2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHuTWM2OD1yLkC3O|A4KM7:TR?= Mn60V2FPT0WU
OS-RC-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XYTmlEPTB;MD6wO|c1QCEQvF2= Ml;RV2FPT0WU
CTB-1 NIrBWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PTU2lEPTB;MD6wO|gyKM7:TR?= NV:2UVdLW0GQR1XS
IST-MES1 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHlTWM2OD1yLkC3PVEzKM7:TR?= Mm\GV2FPT0WU
LS-1034 NV7wZlBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjKW3RKSzVyPUCuNFgxOzVizszN NUnaTIxDW0GQR1XS
HT NYHqUGczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn22TWM2OD1yLkC4NFg3KM7:TR?= MorTV2FPT0WU
NCI-H2141 NVq2VI1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi3TWM2OD1yLkC4NUDPxE1? M{jlWXNCVkeHUh?=
LB2518-MEL M1HQZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPhTWM2OD1yLkC4NVQyKM7:TR?= MUHTRW5ITVJ?
GI-ME-N MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMEi0OVIh|ryP MV;TRW5ITVJ?
TGW NWTKZ3l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrqN2JnUUN3ME2wMlA5PjB5IN88US=> NVTN[lZNW0GQR1XS
SK-NEP-1 NXTobo83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvRTWM2OD1yLkC4OlQyKM7:TR?= NYnhOZo4W0GQR1XS
NOMO-1 NEe5NoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3U[|VsUUN3ME2wMlA6Ojd3IN88US=> NV31Vll6W0GQR1XS
ES6 NYfnXXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;GT3FEUUN3ME2wMlA6PTh7IN88US=> NF;JTJlUSU6JRWK=
NCI-H209 M4nFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1TWM2OD1yLkC5O|g3KM7:TR?= M4LkRnNCVkeHUh?=
GAK NELwe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7DbnVKSzVyPUCuNVAyPiEQvF2= Mn;mV2FPT0WU
BC-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Gz[GlEPTB;MD6xNFM3OSEQvF2= Mn7LV2FPT0WU
KLE NGTXbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK0bZZKSzVyPUCuNVA1PDNizszN NFnrNHJUSU6JRWK=
EW-3 NHG2W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUC5PEDPxE1? MVfTRW5ITVJ?
NKM-1 NVf4WIN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTBwMUGxJO69VQ>? NULzOlhzW0GQR1XS
D-336MG M3jGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojrTWM2OD1yLkGxNlQ1KM7:TR?= MmSxV2FPT0WU
NB69 NX3SPIxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqwTWM2OD1yLkGxN|AyKM7:TR?= Ml\xV2FPT0WU
D-263MG MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\PbGlEPTB;MD6xNVcyOiEQvF2= MnjSV2FPT0WU
KP-N-YS MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMUKyPVEh|ryP NGPFd2tUSU6JRWK=
NCI-H1155 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofvTWM2OD1yLkGyOVU5KM7:TR?= M3vtSnNCVkeHUh?=
BOKU NYPzPXR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMUK1O|kh|ryP M3y4cnNCVkeHUh?=
LAMA-84 NVPWSHc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nZNWlEPTB;MD6xNlk6KM7:TR?= Mn;YV2FPT0WU
Raji MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LJZ2lEPTB;MD6xN|EyPyEQvF2= Mm\CV2FPT0WU
LU-65 MlyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nGc2lEPTB;MD6xN|MxPyEQvF2= NXfmWYJYW0GQR1XS
NCI-H187 NWPnNnJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrxTWM2OD1yLkGzPVI1KM7:TR?= MkPYV2FPT0WU
GCIY MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMUS5NFEh|ryP Mm\yV2FPT0WU
NCI-H2107 M2\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMUWwPEDPxE1? NFrzUXlUSU6JRWK=
NCI-H1522 NYqwNmlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;sTWM2OD1yLkG1NlY3KM7:TR?= NFrWWJFUSU6JRWK=
NB6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z2Z2lEPTB;MD6xOVYzOyEQvF2= MkjPV2FPT0WU
EM-2 Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;xbXY3UUN3ME2wMlE2PzB4IN88US=> MVfTRW5ITVJ?
HCC2218 NHjTeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W2e2lEPTB;MD6xOVk5KM7:TR?= NIPGPIxUSU6JRWK=
NCI-H748 NH3ZWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG4dJdXUUN3ME2wMlE3Ozd4IN88US=> MYPTRW5ITVJ?
MS-1 M{\mTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jn[WlEPTB;MD6xOlU{PyEQvF2= NET5WoFUSU6JRWK=
NB5 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrG[4RKSzVyPUCuNVY2QTdizszN NH3KVmRUSU6JRWK=
OMC-1 MorTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwMU[2PFgh|ryP MWHTRW5ITVJ?
NCI-H345 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXuTWM2OD1yLkG2PVI5KM7:TR?= MlTYV2FPT0WU
L-428 NHHyV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfXTlBKSzVyPUCuNVY6PDVizszN Mlj4V2FPT0WU
SCH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMUi2PFUh|ryP NFrTWW9USU6JRWK=
NCI-H1417 M2rIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLtVld5UUN3ME2wMlE6OjJ5IN88US=> M4P3T3NCVkeHUh?=
COLO-320-HSR NXXNUmVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLGNnZKSzVyPUCuNVk2OzJizszN NYH1NnQ6W0GQR1XS
BT-474 M2\Lfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwMkC4PVIh|ryP MV\TRW5ITVJ?
GDM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\YTWM2OD1yLkKxPVcyKM7:TR?= MUXTRW5ITVJ?
NCI-H2196 M{LLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMkKyN|Uh|ryP NGfY[mJUSU6JRWK=
KP-N-RT-BM-1 NXrFOmVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOye3hlUUN3ME2wMlIzOzR7IN88US=> NX:3eXdvW0GQR1XS
KNS-81-FD NEHW[otIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHxcHRKSzVyPUCuNlI6PThizszN NF;5bFVUSU6JRWK=
COLO-668 NFmzeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\6RY97UUN3ME2wMlI{Pjd3IN88US=> NVrJV5M{W0GQR1XS
C2BBe1 M4jCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj4TWM2OD1yLkK2O|Q4KM7:TR?= MoHUV2FPT0WU
Ramos-2G6-4C10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1f2WWlEPTB;MD6yOlk2PCEQvF2= MoDoV2FPT0WU
CAS-1 NGT4[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfH[oh{UUN3ME2wMlI4ODl4IN88US=> MnzrV2FPT0WU
GOTO M4W3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DU[2lEPTB;MD6yO|g6PCEQvF2= MnGyV2FPT0WU
LP-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7xVYRKSzVyPUCuNlgxPTdizszN Mk[zV2FPT0WU
NCI-SNU-1 M17vNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fYXmlEPTB;MD6yPVQzOiEQvF2= MWrTRW5ITVJ?
EB-3 NHLrcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjmOYlsUUN3ME2wMlI6QTd7IN88US=> NXvkcnBSW0GQR1XS
MHH-NB-11 NYXZSHg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrVOJlKSzVyPUCuN|A1ODJizszN Mn\SV2FPT0WU
SK-N-FI MonWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG4OIRKSzVyPUCuN|E3QTJizszN MkXIV2FPT0WU
HCC2157 NHHwUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoX3TWM2OD1yLkOzPVE{KM7:TR?= MnW1V2FPT0WU
SIMA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwM{S1PFEh|ryP MW\TRW5ITVJ?
MDA-MB-134-VI NGHjPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzzSmV{UUN3ME2wMlM3QTJ6IN88US=> MUHTRW5ITVJ?
NCI-H1694 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwM{eg{txO MkTDV2FPT0WU
EHEB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzsVZNtUUN3ME2wMlM6ODh3IN88US=> M4DvVXNCVkeHUh?=
U-266 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4L2O2lEPTB;MD6zPVg1PiEQvF2= MlLMV2FPT0WU
LC-1F NFvvXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\we2lEPTB;MD60N|c3PSEQvF2= NVr4XXlbW0GQR1XS
SHP-77 Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLMS41KSzVyPUCuOFc5PTVizszN M4rmTnNCVkeHUh?=
LS-513 NV7WclZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknaTWM2OD1yLkS5N|A4KM7:TR?= NWHoUlBZW0GQR1XS

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
体内試験

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • 濃度: 0.1-100 pM
  • 反応時間: 72 hours
  • 実験の流れ:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (参考用のみ)
動物試験:

[4]

+ 展開
  • 動物モデル: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • 製剤: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • 投薬量: 20 mg/kg
  • 投与方法: Administered via i.v.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
混合させたのち直ちに使用することを推奨します。
6mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 853.91
化学式

C47H51NO14

CAS No. 33069-62-4
保管
in solvent
別名 NSC 125973

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 質問2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associatedシグナル伝達経路

相関Microtubule Associated製品

Tags: Paclitaxelを買う | Paclitaxel ic50 | Paclitaxel供給者 | Paclitaxelを購入する | Paclitaxel費用 | Paclitaxel生産者 | オーダーPaclitaxel | Paclitaxel化学構造 | Paclitaxel分子量 | Paclitaxel代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID